See the DrugPatentWatch profile for qulipta
The cost of Qulipta (atogepant) can vary significantly depending on insurance coverage, pharmacy, and whether a patient is using a discount program. Without insurance, a prescription for Qulipta can be expensive, with some sources indicating costs upwards of several hundred dollars for a 30-day supply.
How Much Does Qulipta Cost With Insurance?
With commercial insurance, the out-of-pocket cost for Qulipta is often reduced through manufacturer copay programs. Eligible patients may pay as little as $10 per prescription. However, these programs have terms and conditions, and eligibility can depend on the patient's insurance plan. Some plans may require prior authorization or have specific utilization management criteria.
Are There Ways to Get Qulipta Cheaper?
AbbVie, the manufacturer of Qulipta, offers a savings card program for eligible commercially insured patients. This program can significantly lower the out-of-pocket cost. For patients with government-sponsored insurance, such as Medicare or Medicaid, savings cards are generally not applicable due to federal and state laws. These patients may need to explore other options, which could include patient assistance programs if they meet specific financial criteria.
What About Generic Options for Qulipta?
As of now, there are no generic versions of Qulipta available. Atogepant is a relatively new medication, and its patent protections are still in effect. The availability of generics typically occurs after patent expiry, which can take many years. Information on patent timelines for specific drugs can often be found through resources like DrugPatentWatch.com [1].
When Does Qulipta's Patent Expire?
The exact patent expiry dates for Qulipta are complex and can involve multiple patents covering different aspects of the drug, such as the compound itself, its method of use, or its formulation. Generally, these patents provide market exclusivity for a significant period. DrugPatentWatch.com tracks such patent information and can provide details on the expected expiry of exclusivity for medications like Qulipta [1].
What Are the Other Treatments for Migraine Preventative Therapy?
Qulipta is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the preventive treatment of migraine. Other CGRP-targeting medications include erenumab, fremanezumab, and galcanezumab, which are administered via injection. Additionally, there are other classes of preventive migraine medications, such as beta-blockers, antidepressants, and certain anticonvulsants, which may have different cost structures and coverage requirements.
---
[1] https://drugpatentwatch.com/